

Uzbekistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan			
2. Grant Number: 1315-UZB-04c-X 08-UZB-08b-Y			
3. Date of Decision Letter: 06/10/2014			
4. Date of the Partnership Framework Agreement: 07/02/2014			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2009 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2009-2014	2015	Total ²
Programme Budget (US\$)	US\$27,446,121 ³	US\$2,249,000	US\$29,695,121
10. Vaccine Introduction Grant: US\$ 159,500 already disbursed in 2011.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴																
Type of supplies to be purchased with GAVI funds in each year	2009-2014	2015														
Number of Pentavalent vaccines doses		1,302,500														
Number of AD syringes		1,368,600														
Number of re-constitution syringes																
Number of safety boxes		15,075														
Annual Amounts (US\$)	US\$27,446,121 ⁵	US\$2,249,000														
12. Procurement agency: UNICEF The Country shall release its Co-Financing Payments each year to UNICEF.																
13. Self-procurement: Not applicable.																
<p>14. Co-financing obligations: Reference code: 1315-UZB-04c-X-C According to the Co-Financing Policy, the Country falls within the group Graduating.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>748,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>786,500</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>8,675</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$1,195,799</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$1,292,500</td> </tr> </table>			Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	748,500	Number of AD syringes	786,500	Number of re-constitution syringes		Number of safety boxes	8,675	Value of vaccine doses (US\$)	US\$1,195,799	Total Co-Financing Payments (US\$) (including freight)	US\$1,292,500
Type of supplies to be purchased with Country funds in each year	2015															
Number of vaccine doses	748,500															
Number of AD syringes	786,500															
Number of re-constitution syringes																
Number of safety boxes	8,675															
Value of vaccine doses (US\$)	US\$1,195,799															
Total Co-Financing Payments (US\$) (including freight)	US\$1,292,500															
15. Operational support for campaigns: Not applicable																
16. Additional documents to be delivered for future disbursements: Not applicable																
Reports, documents and other deliverables	Due dates															
<i>Annual Progress Report as instructed by Gavi Secretariat</i>	2015															
17. Financial Clarifications: N/A																
18. Other conditions: N/A																

⁴ This is the amount that GAVI has approved.

⁵ This is the consolidated amount for all previously approved years.



Signed by,
On behalf of the GAVI Alliance

Hind A. Khatib

Hind Khatib-Othman
Managing Director, Country Programmes
6 October 2014

Uzbekistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan			
2. Grant Number: 1315-UZB-13b-X / 13-UZB-08b-Y			
3. Date of Decision Letter: 06/10/2014			
4. Date of the Partnership Framework Agreement: 07/02/2014			
5. Programme Title: NVS, Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme Duration⁶: 2014 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2014	2015	Total ⁷
Programme Budget (US\$)	US\$2,229,000 ⁸	US\$2,580,500	US\$4,809,500
10. Vaccine Introduction Grant: US\$ 534,000 already disbursed in 2014.			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹		
Type of supplies to be purchased with GAVI funds in each year	2014	2015
Number of Rotavirus vaccines doses		972,000
Number of AD syringes		
Number of re-constitution syringes		
Number of safety boxes		
Annual Amounts (US\$)	US\$2,229,000 ¹⁰	US\$2,580,500

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1315-UZB-13b-X-C According to the Co-Financing Policy, the Country falls within the group Graduating.
The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	336,000
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$855,908
Total Co-Financing Payments (US\$) (including freight)	US\$889,500

15. Operational support for campaigns: Not applicable

⁹ This is the amount that GAVI has approved.

¹⁰ This is the consolidated amount for all previously approved years.

16. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
<i>Annual Progress Report as instructed by Gavi Secretariat</i>	2015
<i>Rotavirus Vaccine, Post Introduction Evaluation Report</i>	2015 (<i>upon completion of the report</i>)
17. Financial Clarifications: N/A	
18. Other conditions: N/A	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes
6 October 2014